Min Zhuo
Research Subjects
Research Interests
Min Zhuo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Julie M. Paik
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
3 shared publications Ancilla W. Fernandes
Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey
2 shared publications- John J. Sim
Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, United States
2 shared publications Mercedes A. Munis
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
2 shared publications- Qiaoling Chen
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
2 shared publications Asher D. Schachter
Visterra Inc., Waltham, Massachusetts
1 shared publication
Latest Publications
- 7 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 296-305
Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS
Key Points: Among 228 FSGS patients treated with immunosuppression, only 55% achieved remission with relapse rates of 63% and 74% by 2 years. Over a median follow-up of 4 years, 39% of FSGS treated patients progressed to kidney failure, and a total of 27% died. Nonresponders to immunosuppression had a >2-fold risk of kidney failure compared with responders. Background: FSGS has a variable response to immunosuppressive (IS) therapy and high relapse rates. Lack of US Food and Drug Administration–approved therapies underscore the need for real-world evidence to better understand treatment patterns and outcomes. This study aimed to evaluate treatment response, relapse patterns, and kidney outcomes among patients with primary FSGS. Methods: A retrospective cohort study was performed within 14 medical centers of an integrated health system. Patients (18 years or older) with biopsy-confirmed primary FSGS treated with IS between 2010 and 2021 were included. Treatment response, assessed at up to 8 months, was categorized as complete remission: urine protein-to-creatinine ratio (UPCR) 50% from baseline and between 0.3 and 3.5 g/g, and no remission. Relapse was defined as loss of remission within 2 years. Outcomes, including ESKD (treatment with dialysis or transplant) and mortality, were analyzed using Fine-Gray subdistribution hazard ratio (sHR) models. Results: Among 228 patients treated with IS, 55% achieved remission (12% complete remission, 43% partial remission), with relapse rates of 63% and 75% by 2 years. The median follow-up was 4 years (interquartile range, 2.0–7.6), during which 88 (39%) progressed to ESKD. A total of 62 (27%) patients died, with 33 (15%) deaths occurring before reaching ESKD. Nonresponders had a higher risk of ESKD compared with responders (sHR, 2.22; 95% confidence interval [CI], 1.41 to 3.49). Baseline eGFR 2 was strongly associated with risk of ESKD (sHR for eGFR of P < 0.001), while baseline proteinuria (UPCR >3.5 g/g) was NS. Asian/Pacific Islander patients exhibited the highest ESKD risk among racial/ethnic groups (sHR, 2.03; 95% CI, 1.07 to 3.84). Conclusions: Approximately half of FSGS patients achieved remission with IS, but relapse rates were high, and nearly 40% progressed to ESKD. Nonresponders and low baseline eGFR had the highest risk. These findings underscore the need for novel therapies to achieve durable disease control, lower relapse rates, and improve outcomes in FSGS.
- 7 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 296-305
Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS
Key Points: Among 228 FSGS patients treated with immunosuppression, only 55% achieved remission with relapse rates of 63% and 74% by 2 years. Over a median follow-up of 4 years, 39% of FSGS treated patients progressed to kidney failure, and a total of 27% died. Nonresponders to immunosuppression had a >2-fold risk of kidney failure compared with responders. Background: FSGS has a variable response to immunosuppressive (IS) therapy and high relapse rates. Lack of US Food and Drug Administration–approved therapies underscore the need for real-world evidence to better understand treatment patterns and outcomes. This study aimed to evaluate treatment response, relapse patterns, and kidney outcomes among patients with primary FSGS. Methods: A retrospective cohort study was performed within 14 medical centers of an integrated health system. Patients (18 years or older) with biopsy-confirmed primary FSGS treated with IS between 2010 and 2021 were included. Treatment response, assessed at up to 8 months, was categorized as complete remission: urine protein-to-creatinine ratio (UPCR) 50% from baseline and between 0.3 and 3.5 g/g, and no remission. Relapse was defined as loss of remission within 2 years. Outcomes, including ESKD (treatment with dialysis or transplant) and mortality, were analyzed using Fine-Gray subdistribution hazard ratio (sHR) models. Results: Among 228 patients treated with IS, 55% achieved remission (12% complete remission, 43% partial remission), with relapse rates of 63% and 75% by 2 years. The median follow-up was 4 years (interquartile range, 2.0–7.6), during which 88 (39%) progressed to ESKD. A total of 62 (27%) patients died, with 33 (15%) deaths occurring before reaching ESKD. Nonresponders had a higher risk of ESKD compared with responders (sHR, 2.22; 95% confidence interval [CI], 1.41 to 3.49). Baseline eGFR 2 was strongly associated with risk of ESKD (sHR for eGFR of P < 0.001), while baseline proteinuria (UPCR >3.5 g/g) was NS. Asian/Pacific Islander patients exhibited the highest ESKD risk among racial/ethnic groups (sHR, 2.03; 95% CI, 1.07 to 3.84). Conclusions: Approximately half of FSGS patients achieved remission with IS, but relapse rates were high, and nearly 40% progressed to ESKD. Nonresponders and low baseline eGFR had the highest risk. These findings underscore the need for novel therapies to achieve durable disease control, lower relapse rates, and improve outcomes in FSGS.
- Open Access
- 12 December 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (2) , 229-238
Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021
Key Points: Primary FSGS is a rare immune mediated glomerulopathy that accounted for 16.6% for all FSGS reported biopsies among a diverse patient population. From 2010 to 2021, the standardized incidence of primary FSGS was estimated at 1.7 cases per 100,000 patient-years. The highest incidence of primary FSGS was observed among Black (3.2) and Asian (2.7 cases per 100,000 patient-years) people. Background: Focal segmental glomerulosclerosis (FSGS) refers to a pattern of glomerular injury but also includes primary FSGS which is considered as an immune-mediated glomerulopathy. We sought to determine the incidence of primary FSGS and proportion of patients with FSGS who have primary FSGS among a large diverse patient population in the United States. Methods: A cross-sectional study (2010–2021) was performed within an integrated health system in patients (age 18 or older) with biopsy-proven FSGS. Among biopsies with FSGS as the first diagnosis on pathology report, chart reviews were performed to determine primary FSGS, defined as podocyte foot process effacement ≥80% on electron microscopy. The proportion of patients with primary FSGS and annual incidence rate (IR) (per 100,000 patient-years) were calculated. Standardized IR were determined by age, sex, and race and ethnicity based on US population structure of the 5-year (2018–2022) American Community Survey estimates. Results: We identified 3838 patients with FSGS reported on biopsy. Among 1502 with FSGS as the principal diagnosis, 637 met criteria for primary FSGS (mean [SD] age 55.5 years [17.9], 56.5% male, 35.6% Hispanic, 28.7% White, 17.9% Asian/Pacific Islander, and 16.0% Black). The mean standardized IR (confidence interval) of primary FSGS was 1.7 (0.9 to 2.5) per 100,000 patient-years during the study period. The standardized annual IR ranged from 1.3 to 2.4 per 100,000 patient-years. IR (per 100,000 patient-years) were highest among Black (3.2), Asian (2.7), and Pacific Islander (2.8) patients. Conclusions: Primary FSGS accounted for 16.6% of biopsy-proven FSGS. Primary FSGS is a likely a rare disease with incidence highest among Black, Asian, and Pacific Islander people. More precise identification of primary FSGS may facilitate work to improve understanding of this glomerulopathy and improve kidney outcomes.
- 12 December 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (2) , 229-238
Open AccessIncidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021
Key Points: Primary FSGS is a rare immune mediated glomerulopathy that accounted for 16.6% for all FSGS reported biopsies among a diverse patient population. From 2010 to 2021, the standardized incidence of primary FSGS was estimated at 1.7 cases per 100,000 patient-years. The highest incidence of primary FSGS was observed among Black (3.2) and Asian (2.7 cases per 100,000 patient-years) people. Background: Focal segmental glomerulosclerosis (FSGS) refers to a pattern of glomerular injury but also includes primary FSGS which is considered as an immune-mediated glomerulopathy. We sought to determine the incidence of primary FSGS and proportion of patients with FSGS who have primary FSGS among a large diverse patient population in the United States. Methods: A cross-sectional study (2010–2021) was performed within an integrated health system in patients (age 18 or older) with biopsy-proven FSGS. Among biopsies with FSGS as the first diagnosis on pathology report, chart reviews were performed to determine primary FSGS, defined as podocyte foot process effacement ≥80% on electron microscopy. The proportion of patients with primary FSGS and annual incidence rate (IR) (per 100,000 patient-years) were calculated. Standardized IR were determined by age, sex, and race and ethnicity based on US population structure of the 5-year (2018–2022) American Community Survey estimates. Results: We identified 3838 patients with FSGS reported on biopsy. Among 1502 with FSGS as the principal diagnosis, 637 met criteria for primary FSGS (mean [SD] age 55.5 years [17.9], 56.5% male, 35.6% Hispanic, 28.7% White, 17.9% Asian/Pacific Islander, and 16.0% Black). The mean standardized IR (confidence interval) of primary FSGS was 1.7 (0.9 to 2.5) per 100,000 patient-years during the study period. The standardized annual IR ranged from 1.3 to 2.4 per 100,000 patient-years. IR (per 100,000 patient-years) were highest among Black (3.2), Asian (2.7), and Pacific Islander (2.8) patients. Conclusions: Primary FSGS accounted for 16.6% of biopsy-proven FSGS. Primary FSGS is a likely a rare disease with incidence highest among Black, Asian, and Pacific Islander people. More precise identification of primary FSGS may facilitate work to improve understanding of this glomerulopathy and improve kidney outcomes.
- Open Access
- 4 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6927
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence
A PRoliferation-Inducing Ligand (APRIL), the thirteenth member of the tumor necrosis factor superfamily, plays a key role in the regulation of activated B cells, the survival of long-lived plasma cells, and immunoglobulin (Ig) isotype class switching. Several lines of evidence have implicated APRIL in the pathogenesis of IgA nephropathy (IgAN). Globally, IgAN is the most common primary glomerulonephritis, and it can progress to end-stage kidney disease; yet, disease-modifying treatments for this condition have historically been lacking. The preliminary data in ongoing clinical trials indicate that APRIL inhibition can reduce proteinuria and slow the rate of kidney disease progression by acting at an upstream level in IgAN pathogenesis. In this review, we examine what is known about the physiologic roles of APRIL and evaluate the experimental and epidemiological evidence describing how these normal biologic processes are thought to be subverted in IgAN. The weight of the preclinical, clinical, and genetic data supporting a key role for APRIL in IgAN has galvanized pharmacologic research, and several anti-APRIL drug candidates have now entered clinical development for IgAN. Herein, we present an overview of the clinical results to date. Finally, we explore where more research and evidence are needed to transform potential therapies into clinical benefits for patients with IgAN.
- 4 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6927
Open AccessA PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence
A PRoliferation-Inducing Ligand (APRIL), the thirteenth member of the tumor necrosis factor superfamily, plays a key role in the regulation of activated B cells, the survival of long-lived plasma cells, and immunoglobulin (Ig) isotype class switching. Several lines of evidence have implicated APRIL in the pathogenesis of IgA nephropathy (IgAN). Globally, IgAN is the most common primary glomerulonephritis, and it can progress to end-stage kidney disease; yet, disease-modifying treatments for this condition have historically been lacking. The preliminary data in ongoing clinical trials indicate that APRIL inhibition can reduce proteinuria and slow the rate of kidney disease progression by acting at an upstream level in IgAN pathogenesis. In this review, we examine what is known about the physiologic roles of APRIL and evaluate the experimental and epidemiological evidence describing how these normal biologic processes are thought to be subverted in IgAN. The weight of the preclinical, clinical, and genetic data supporting a key role for APRIL in IgAN has galvanized pharmacologic research, and several anti-APRIL drug candidates have now entered clinical development for IgAN. Herein, we present an overview of the clinical results to date. Finally, we explore where more research and evidence are needed to transform potential therapies into clinical benefits for patients with IgAN.
- 22 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (9) , 1414-1423
Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer
- 22 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (9) , 1414-1423
Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer
- 31 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (3) , 455-464
Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis
Key Points: The prescribing patterns of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the CKD population remain largely unknown. Prescription of SGLT-2i was low in patients with CKD, particularly those without diabetes. Younger Black men with a history of heart failure and cardiologist visit were associated with higher odds of SGLT-2i prescription. Background: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic kidney disease (CKD), regardless of diabetes status. However, the prescribing patterns of these novel therapeutics in the CKD population in real-world settings remain largely unknown. Methods: This cross-sectional study included adults with stages 3–5 CKD included in the Mass General Brigham (MGB) CKD registry in March 2021. We described the adoption of SGLT-2i therapy and evaluated factors associated with SGLT-2i prescription using multivariable logistic regression models in the CKD population, with and without diabetes. Results: A total of 72,240 patients with CKD met the inclusion criteria, 31,688 (44%) of whom were men and 61,265 (85%) White. A total of 22,653 (31%) patients were in the diabetic cohort, and 49,587 (69%) were in the nondiabetic cohort. SGLT-2i prescription was 6% in the diabetic cohort and 0.3% in the nondiabetic cohort. In multivariable analyses, younger Black men with a history of heart failure, use of cardiovascular medications, and at least one cardiologist visit in the previous year were associated with higher odds of SGLT-2i prescription in both diabetic and nondiabetic cohorts. Among patients with diabetes, advanced CKD stages were associated with lower odds of SGLT-2i prescription, whereas urine dipstick test and at least one subspecialist visit in the previous year were associated with higher odds of SGLT-2i prescription. In the nondiabetic cohort, CKD stage, urine dipstick test, and at least one nephrologist visit in the previous year were not significantly associated with SGLT-2i prescription. Conclusions: In this registry study, prescription of SGLT-2i was low in the CKD population, particularly among patients without diabetes.
- 31 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (3) , 455-464
Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis
Key Points: The prescribing patterns of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the CKD population remain largely unknown. Prescription of SGLT-2i was low in patients with CKD, particularly those without diabetes. Younger Black men with a history of heart failure and cardiologist visit were associated with higher odds of SGLT-2i prescription. Background: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic kidney disease (CKD), regardless of diabetes status. However, the prescribing patterns of these novel therapeutics in the CKD population in real-world settings remain largely unknown. Methods: This cross-sectional study included adults with stages 3–5 CKD included in the Mass General Brigham (MGB) CKD registry in March 2021. We described the adoption of SGLT-2i therapy and evaluated factors associated with SGLT-2i prescription using multivariable logistic regression models in the CKD population, with and without diabetes. Results: A total of 72,240 patients with CKD met the inclusion criteria, 31,688 (44%) of whom were men and 61,265 (85%) White. A total of 22,653 (31%) patients were in the diabetic cohort, and 49,587 (69%) were in the nondiabetic cohort. SGLT-2i prescription was 6% in the diabetic cohort and 0.3% in the nondiabetic cohort. In multivariable analyses, younger Black men with a history of heart failure, use of cardiovascular medications, and at least one cardiologist visit in the previous year were associated with higher odds of SGLT-2i prescription in both diabetic and nondiabetic cohorts. Among patients with diabetes, advanced CKD stages were associated with lower odds of SGLT-2i prescription, whereas urine dipstick test and at least one subspecialist visit in the previous year were associated with higher odds of SGLT-2i prescription. In the nondiabetic cohort, CKD stage, urine dipstick test, and at least one nephrologist visit in the previous year were not significantly associated with SGLT-2i prescription. Conclusions: In this registry study, prescription of SGLT-2i was low in the CKD population, particularly among patients without diabetes.
- Open Access
- 23 November 2021
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 52 (12) , 919-928
Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013–2017
Introduction: The medication burden of patients with end-stage renal disease (ESRD) on hemodialysis, a patient population with a high comorbidity burden and complex care requirements, is among the highest of any of the chronic diseases. The goal of this study was to describe the medication burden and prescribing patterns in a contemporary cohort of patients with ESRD on hemodialysis in the USA. Methods: We used the United States Renal Data System database from January 1, 2013, and December 31, 2017, to quantify the medication burden of patients with ESRD on hemodialysis aged ≥18 years. We calculated the average number of prescription medications per patient during each respective year (January–December), number of medications within classes, including potentially harmful medications, and trends in the number of medications and classes over the 5-year study period. Results: We included a total of 163,228 to 176,133 patients from 2013 to 2017. The overall medication burden decreased slightly, from a mean of 7.4 (SD 3.8) medications in 2013 to 6.8 (SD 3.6) medications in 2017. Prescribing of potentially harmful medications decreased over time (74.0% with at least one harmful medication class in 2013–68.5% in 2017). In particular, the prescribing of non-benzodiazepine hypnotics, benzodiazepines, and opioids decreased from 2013 to 2017 (12.2%–6.3%, 23.4%–19.3%, and 60.0%–53.4%, respectively). This trend was consistent across subgroups of age, sex, race, and low-income subsidy status. Conclusions: Patients with ESRD on hemodialysis continued to have a high overall medication burden, with a slight reduction over time accompanied by a decrease in prescribing of several classes of harmful medications. Continued emphasis on assessment of appropriateness of high medication burden in patients with ESRD is needed to avoid exposure to potentially harmful or futile medications in this patient population.
- 23 November 2021
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 52 (12) , 919-928
Open AccessMedication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013–2017
Introduction: The medication burden of patients with end-stage renal disease (ESRD) on hemodialysis, a patient population with a high comorbidity burden and complex care requirements, is among the highest of any of the chronic diseases. The goal of this study was to describe the medication burden and prescribing patterns in a contemporary cohort of patients with ESRD on hemodialysis in the USA. Methods: We used the United States Renal Data System database from January 1, 2013, and December 31, 2017, to quantify the medication burden of patients with ESRD on hemodialysis aged ≥18 years. We calculated the average number of prescription medications per patient during each respective year (January–December), number of medications within classes, including potentially harmful medications, and trends in the number of medications and classes over the 5-year study period. Results: We included a total of 163,228 to 176,133 patients from 2013 to 2017. The overall medication burden decreased slightly, from a mean of 7.4 (SD 3.8) medications in 2013 to 6.8 (SD 3.6) medications in 2017. Prescribing of potentially harmful medications decreased over time (74.0% with at least one harmful medication class in 2013–68.5% in 2017). In particular, the prescribing of non-benzodiazepine hypnotics, benzodiazepines, and opioids decreased from 2013 to 2017 (12.2%–6.3%, 23.4%–19.3%, and 60.0%–53.4%, respectively). This trend was consistent across subgroups of age, sex, race, and low-income subsidy status. Conclusions: Patients with ESRD on hemodialysis continued to have a high overall medication burden, with a slight reduction over time accompanied by a decrease in prescribing of several classes of harmful medications. Continued emphasis on assessment of appropriateness of high medication burden in patients with ESRD is needed to avoid exposure to potentially harmful or futile medications in this patient population.
- 1 January 2021
- Published by Elsevier in Seminars in Nephrology
- Vol. 41 (1) , 33-41
Opioid Use in the Nondialysis Chronic Kidney Disease Population
- 1 January 2021
- Published by Elsevier in Seminars in Nephrology
- Vol. 41 (1) , 33-41
Opioid Use in the Nondialysis Chronic Kidney Disease Population